Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Revenue of Mineralys Therapeutics, Inc. (MLYS)
Revenue in 2023 (TTM): $
According to Mineralys Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Mineralys Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $-84,657,000 | $-71,898,000 | $-71,898,000 |
| 2022 | $ | $ | $-31,479,000 | $-29,799,000 | $-29,799,000 |
| 2021 | $ | $ | $-18,724,000 | $-19,408,000 | $-19,408,000 |
| 2020 | $ | $ | $-2,944,000 | $-3,426,000 | $-3,426,000 |